SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:30 am Eastern Time.
To access a live webcast or replay of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com.
TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1/2 development; and TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.
|Company Contact:||Investor Contact:|
|Charles Theuer||Brian Ritchie|
|Chief Executive Officer||LifeSci Advisors LLC|
|(858) 550-0780||(212) 915-2578|
- Optical Coatings Market Set to Soar at 8.8% CAGR, Projected to Reach US$ 22,598.7 Million by 2032 | Future Market Insights, Inc. - September 26, 2023
- Smart Speaker Market Accelerates at 32.5% CAGR to Reach US$ 110 Billion by 2033: Fact.MR Report - September 26, 2023
- Conference Room Solutions Market Surges to US$ 6,068.1 Million by 2033, Propelled by a Remarkable CAGR of 14.8% | Future Market Insights, Inc. - September 26, 2023